• Lead
• Features
• Development Stage
• Indications

5-HT_2C agonists for CNS disorders

• BMB-101
• • Selective and biased 2C agonist, low 5-HT _2A/2B
  • Biased Agonism with minimal Arrestin recruitment
  • Suitable for chronic dosign
• Cliical Studies - Phase 1
• Dravet Syndrome

  AD psychosis
  Addictions
  Binge Eating

5-HT_2A agonists for the treatment of depression

• BMB-202
• • Selective 5-HT_2a "Fast-On-Fast_Off" compound
  • High C_max and short plasma half life
  • 2-fold more potent than psilocin at 5-HT_2A
• IND-enabling tox
• Depression

  Anxiety
  PTSD

• BMB-xxx
• • Mixed 5-HT _2A/2C compound
  • 10-fold more potent than psilocin at 5-HT _2A
• ADMEPK profiling

• Neurology /
  Neuropsychiatric
  Indication

Non-hallucinogenic psychoplastrogens

• • Non-hallucinogenic 5-HT _2A agonists promoting
  • neuroplasticity in brain (investigational program)
• Pilot study

• Neurology /
  Neuropsychiatric
  Indication